Previous research has demonstrated that signatures based on the TNF family can serve as effective prognostic tools and predict the response to immunotherapy and chemotherapy in various cancers, such as lung adenocarcinoma (LUAD) and colorectal cancer [5, 6]. The gene discussed is TNF; the disease is cancer.